• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Bolt Biotherapeutics, Inc. - Common Stock (NQ:BOLT)

    5.240 +0.280 (+5.65%)
    Streaming Delayed Price Updated: 3:52 PM EDT, Oct 3, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 74,917
    Open 5.120
    Bid (Size) 5.200 (2)
    Ask (Size) 5.360 (3)
    Prev. Close 4.960
    Today's Range 4.981 - 5.470
    52wk Range 4.590 - 14.36
    Shares Outstanding 37,950,986
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Thursday's Intraday Session
     
    Via Benzinga
    Fidus Investment, Rocket Companies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
     
    Via Benzinga

    Performance

    YTD
    -54.0%
    -54.0%
    1 Month
    +5.2%
    +5.2%
    3 Month
    -11.5%
    -11.5%
    6 Month
    -33.7%
    -33.7%
    1 Year
    -59.5%
    -59.5%

    More News

    Read More
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Bolt Revenue Jumps 39 Percent in Q2
    Via The Motley Fool
    Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Stay updated with the stocks that are on the move in today's after-hours session.
    Via Chartmill
    Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    Bolt Biotherapeutics to Participate in Upcoming March Conferences
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    Bolt Biotherapeutics Announces Changes to its Board of Directors
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire

    Frequently Asked Questions

    Is Bolt Biotherapeutics, Inc. - Common Stock publicly traded?
    Yes, Bolt Biotherapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Bolt Biotherapeutics, Inc. - Common Stock trade on?
    Bolt Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Bolt Biotherapeutics, Inc. - Common Stock?
    The ticker symbol for Bolt Biotherapeutics, Inc. - Common Stock is BOLT on the Nasdaq Stock Market
    What is the current price of Bolt Biotherapeutics, Inc. - Common Stock?
    The current price of Bolt Biotherapeutics, Inc. - Common Stock is 5.240
    When was Bolt Biotherapeutics, Inc. - Common Stock last traded?
    The last trade of Bolt Biotherapeutics, Inc. - Common Stock was at 10/03/25 03:52 PM ET
    What is the market capitalization of Bolt Biotherapeutics, Inc. - Common Stock?
    The market capitalization of Bolt Biotherapeutics, Inc. - Common Stock is 198.86M
    How many shares of Bolt Biotherapeutics, Inc. - Common Stock are outstanding?
    Bolt Biotherapeutics, Inc. - Common Stock has 199M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.